Denali Therapeutics (DNLI) announced the publication of results from the open-label Phase 1/2 clinical trial of its investigational, ...

Tividenofusp alfa treatment showed reduction and normalization in key disease biomarkers, stabilization or improvement in clinical endpoints including adaptive behavior, cognition and hearing, and ...

Abstract: In this study, two problems of flip chip on glass-core package substrate will be investigated. The first problem deals with the flip chip on glass-core package substrate with microbumps and ...

Obesity is a global epidemic and a major cause of morbidity and mortality because it increases the risk for comorbidities, ...

Aptamer Group plc, a developer of synthetic oligonucleotide-based binding reagents for life sciences applications, and ...

DNA origami cages constrain individual proteins toward preferred orientations on electrodes, dramatically improving ...

Bacterial patterns invisible to the eye reveal hidden information only with correct biochemical triggers, creating ...

Creative BioMart is pleased to announce the upgrade of its protein deubiquitination assay service, providing researchers with a more sensitive, flexible, and high-throughput platform to study ...

BioMarin Pharmaceutical Inc. and Amicus Therapeutics announced today that BioMarin has entered into a definitive agreement to acquire Amicus for $14.50 per share in an all-cash transaction for a total ...

Data from a new mouse model may help advance therapeutic development in celiac disease, including improved TG2 inhibitors and ...

Researchers have captured real-time "molecular movies" showing how an enzyme changes shape during catalysis. The study was ...

Results showed CNS target engagement with reduction in GCase substrate glucosylsphingosine (GluSph) in cerebrospinal fluid (CSF), a prespecified ...